Adobe
ADBE
D.R. Horton
DHI
Lennar Corp
LEN
Toll Brothers
TOL
Petroleo Brasileiro SA Petrobras
PBR
US Stock MarketDetailed Quotes
FDMT 4D Molecular Therapeutics
- 5.760
- -0.050-0.86%
Trading Dec 26 15:54 ET
266.27MMarket Cap-2.02P/E (TTM)
5.785High5.590Low459.06KVolume5.770Open5.810Pre Close2.61MTurnover1.46%Turnover RatioLossP/E (Static)46.23MShares36.25052wk High0.48P/B180.59MFloat Cap5.58052wk Low--Dividend TTM31.35MShs Float55.110Historical High--Div YieldTTM3.36%Amplitude5.320Historical Low5.691Avg Price1Lot Size
About 4D Molecular Therapeutics Company
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.
Company Profile
SymbolFDMT
Company Name4D Molecular Therapeutics
Issue Price23.00
Founded2013
CEOMr. David Kirn, M.D.
MarketNASDAQ
Employees147
Fiscal Year Ends12-31
Address5858 Horton Street,Suite 455
CityEmeryville
ProvinceCalifornia
CountryUnited States of America
Zip Code94608
Phone1-510-505-2680
Company Executives
- Name
- Position
- Salary
- David Kirn, M.D.
- Director and Chief Executive Officer
- 10.29M
- Robert Young Kim, M.D.
- Chief Medical Officer
- 3.96M
- Noriyuki Kasahara, M.D.,PhD
- Chief Scientific Officer
- 488.91K
- Uneek Mehra
- Chief Business Officer, Chief Financial Officer and Principal Accounting Officer
- --
- Dr. Fariborz Kamal, PhD
- President and Chief Operating Officer
- 4.54M
- Dr. John F. Milligan, PhD
- Executive Chairman of the Board
- 581.44K
- Dr. Charles P. Theuer, M.D.,PhD
- Independent Director
- 352.62K
- Susannah Gray, M.B.A.
- Independent Director
- 352.62K
- Shawn Cline Tomasello, M.B.A.
- Independent Director
- 345.12K
- Nancy Miller-Rich
- Independent Director
- 340.12K
- Jacob M. Chacko, M.B.A.,M.D.
- Independent Director
- 352.62K
- Scott Bizily, J.D.,PhD
- Chief Legal and Corporate Secretary
- --
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.